Results 141 to 150 of about 140,103 (295)
ABSTRACT In the phase 2, double‐blind, randomized controlled BEYOND trial (NCT03342404), luspatercept increased hemoglobin levels in patients with non‐transfusion‐dependent β‐thalassemia (NTDT). This study assessed long‐term effects of luspatercept on patient‐reported outcomes (PROs), using data from BEYOND and patients who continued luspatercept ...
Khaled M. Musallam +12 more
wiley +1 more source
Determinants of retinal and choriocapillaris microvascular alterations in pediatric β-thalassemia: an OCTA study. [PDF]
Amin MR, Youssef MM, Ali AA, Hassan LM.
europepmc +1 more source
PSY154 - ECONOMIC BURDEN OF BETA-THALASSEMIA: LITERATURE REVIEW [PDF]
Anna Kotzeva +4 more
openalex +1 more source
Genetic polymorphism of SNPs rs9399137 and rs4895441in HBS1L-MYB and SNP rs766432 in BCL11A among β-thalassemia Egyptian patients. [PDF]
Abdelrahman AA +4 more
europepmc +1 more source
Renal damages in patients with major β-thalassemia [PDF]
Malihe Najafpour +4 more
openalex +1 more source
Osteoporosis risk in alpha and beta thalassemia: An age- and sex-specific retrospective cohort study. [PDF]
Hsu YS, Tseng SC, Chao TF, Chen KH.
europepmc +1 more source
Hemoglobin Nigeria (alpha-81 Ser replaced by Cys):a new variant associated with alpha-thalassemia [PDF]
GR Honig +6 more
openalex +1 more source
The Longitudinal Effect of APOL1 Risk Alleles on Sickle Cell Anemia‐Associated Kidney Function
ABSTRACT Progressive kidney injury is a major cause of morbidity and mortality in sickle cell anemia (SCA). The high risk APOL1 G1/G2 variants contribute to the development of kidney disease in individuals of African ancestry, including those with SCA.
Sara R. Rashkin +7 more
wiley +1 more source

